Scribe Therapeutics (SCTX) Stock Price, News & Analysis

Company Overview

Scribe Therapeutics Inc. is a clinical-stage biotechnology company engineering CRISPR-based technologies into purpose-built in vivo genetic medicines designed to become standard of care treatments for patients suffering from highly prevalent diseases, starting with cardiometabolic disease. Scribe Therapeutics Inc. is based in ALAMEDA, Calif.

Key Stats

• Today's Range: $28.46 to $31.25
• 50-Day Range: N/A
• 52-Week Range: $17.31 to $39.60
• Volume: 165,035 shs
• Average Volume: 227,002 shs
• Market Capitalization: $509.73 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $51.75
• Consensus Rating: Buy

Scribe Therapeutics Stock Analysis - MarketRank™

Scribe Therapeutics scored higher than 94% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Buy

Consensus Rating

Scribe Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on no strong buy ratings, 4 buy ratings, no hold ratings, and no sell ratings.

Upside Potential

Scribe Therapeutics has a consensus price target of $51.75, representing about 78.4% upside from its current price of $29.00.

Amount of Analyst Coverage

Scribe Therapeutics has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: N/A
• Proj. Earnings Growth: N/A

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.62% of the float of Scribe Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Scribe Therapeutics has a short interest ratio ("days to cover") of 2.14, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Scribe Therapeutics has recently increased by 8.23%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Scribe Therapeutics does not currently pay a dividend.

Dividend Growth

Scribe Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: 0.51

News Sentiment

Scribe Therapeutics has a news sentiment score of 0.51. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of companies.

News Coverage This Week

MarketBeat has tracked 7 news articles for Scribe Therapeutics this week, compared to 5 articles on an average week.

Search Interest

Only 6 people have searched for SCTX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

2 people have added Scribe Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 3.6 / 5
• Insider Trading: Acquiring Shares

Cluster Insider Buying

4 insiders have purchased shares of Scribe Therapeutics in the last three months. Multiple insiders buying is a strong bullish signal.

Net Insider Buying

Over the last three months, insiders have purchased a net $56,291,746.00 in company stock, which represents 11.0434% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, Scribe Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $56,291,746.00 in company stock and sold $0.00 in company stock.

Percentage Held by Institutions

Scribe Therapeutics has minimal institutional ownership at this time.

Company Calendar

• Today: 9/02/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: N/A
• Industry: N/A
• Sub-Industry: N/A
• Current Symbol: NASDAQ:SCTX
• CIK: 1853921
• Web: N/A
• Phone: N/A
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Scribe Therapeutics: $51.75
• High Price Target: $60.00
• Low Price Target: $37.00
• Potential Upside/Downside: +78.4%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $36.28 million
• Price / Sales: 14.05
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 17,577,000
• Free Float: N/A
• Market Cap: $509.73 million
• Optionable: N/A
• Beta: N/A